Prediction of Radiotherapy Efficacy in Patients With Triple-negative Breast Cancer

Launched by INSTITUT DE CANCÉROLOGIE STRASBOURG EUROPE · May 13, 2024

Keywords

ClinConnect Summary

This clinical trial is focused on understanding how to predict the risk of recurrence in women with triple-negative breast cancer (TNBC) after they receive treatment. TNBC can come back in some patients within a few years, and researchers want to find out if certain substances in the blood, called cytokines, can help identify patients who are more likely to experience a recurrence. Specifically, they will be looking at levels of IL-1β, IL-5, and IL-6 in the blood during radiotherapy to see if these can be used as warning signs.

To participate in this trial, women must be 18 years or older, have been diagnosed with TNBC, and have undergone either chemotherapy or surgery followed by radiotherapy. They should not have any signs of cancer spreading to other parts of the body, and they need to be covered by the French social security system. If eligible, participants will provide blood samples during their treatment and will help researchers learn more about how to better predict cancer recurrence, ultimately aiming to improve patient care in the future.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• Women with TNBC breast cancer who meet the following criteria:
• • Women aged 18 and over;
• • Any tumor size (pT stage);
• • Regional lymph node pN0 to pN3;
• • Patient with pathologically confirmed TNBC (estrogen and progesterone receptor negative and HER2 negative);
• • Neo- or adjuvant chemotherapy followed by radiotherapy;
• • No evidence of distant metastasis at time of diagnosis;
• • Primary tumor removed by conservative surgery with negative margins;
• • Patient covered by the French social security system (for French patients).
• Exclusion Criteria:
• • Distant metastasis at the time of diagnosis;
• • Pregnant or breast-feeding women;
• • Woman deprived of liberty, under guardianship or trusteeship.
• • Patient unable to give consent
• • Patient unable to speak French
• • Patients unable to undergo regular long-term surveillance.